JP Morgan Chase
CAPR icon

JP Morgan Chase’s Capricor Therapeutics CAPR Stock Holding History

JP Morgan Chase’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-150,000
Closed -$1.49M – 7417
2025
Q2 		$1.49M Buy
+150,000
New +$1.58M ﹤0.01% 4128

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase's CAPR Position: Q2 2026 in Review

JP Morgan Chase increased its Capricor Therapeutics (CAPR) stake by 5.5% in Q2 2026, buying an estimated $573K and bringing the position to 362,501 shares worth $8.69M. The position accounts for ﹤0.01% of the portfolio, ranked #2933.

JP Morgan Chase first reported a position in CAPR in Q2 2017 and has held it in 15 quarters since. The position peaked at $10.7M in Q4 2025. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • JP Morgan Chase held 362,501 shares of Capricor Therapeutics worth $8.69M as of Q2 2026.
  • JP Morgan Chase bought 18,888 Capricor Therapeutics shares in Q2 2026, an estimated $573K.
  • Capricor Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2933 holding.
  • JP Morgan Chase first reported a position in Capricor Therapeutics in Q2 2017 and has held it in 15 quarters since.
  • JP Morgan Chase's Capricor Therapeutics position peaked at $10.7M in Q4 2025.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.